NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025
Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the…
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Partnership marks AbbVie’s entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global infrastructure for developing and commercializing therapies for patients in needAbbVie (NYSE: ABBV) and Gubra A/S…
Annual Report 2024: Excellent performance across Gubra
Gubra Annual Report 2024 (incl Sustainability Report)
CEO video statement. Annual Report 2024.
A year defined by progress, innovation, and impact 2024 was a year defined by progress, innovation, and impact. For the CRO business, performance was strong with an organic revenue growth of 31%. In the Discovery & Partnerships business several projects…
Gubra appoints new Chief Operating Officer
Gubra is excited to announce the appointment of Anne-Marie Levy Rasmussen as the company’s new Chief Operating Officer (COO). Anne-Marie brings a strong international experience and track record from global pharma companies such as GlaxoSmithKline and Bavarian Nordic within operational…
Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist
Today, Gubra A/S (“Company”), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration with Amylyx Pharmaceuticals, Inc. (“Amylyx”) for the development of a potential novel long-acting GLP-1 receptor antagonist…
Gubra announces positive GUBamy Phase 1 SAD data (correction)
The correction in this announcement refers solely that that company announcement published today at 5.41pm CET should have been labelled as inside information and not company information. The content in the release is completely unchanged and provided again below.Gubra announces…
Gubra announces positive GUBamy Phase 1 SAD data
Gubra announces positive results from the single ascending dose (SAD) phase 1 clinical trial with the long-acting amylin analogue GUBamy: GUBamy was well tolerated with adverse events being predominantly GI related, mild and transient. GUBamy had a favourable pharmacokinetic profile…
CEO video statement. 2024 Q3-results
Another strong quarter For the CRO business, performance was strong with organic revenue growth year-over-year of 25% for the quarter and 31% for the first nine months. Within the Discovery & Partnerships (D&P) business, significant progress was made across several…
Trading statement Q3-2024: Another strong quarter
Today, Gubra releases its results for the third quarter of 2024. Significant progress was made across several R&D projects, not the least by advancement for the anti-obesity Amylin program where topline results from the Phase 1 Single Ascending Dose (SAD)…